YI Elshimali, H Khaddour, M Sarkissyan, Y Wu… - International journal of …, 2013 - mdpi.com
Qualitative and quantitative testing of circulating cell free DNA (CCFDNA) can be applied for the management of malignant and benign neoplasms. Detecting circulating DNA in cancer …
K Warton, KL Mahon, G Samimi - Endocrine-related cancer, 2016 - erc.bioscientifica.com
The aim of the present study was to perform a systematic review of published studies to provide a robust estimation of the use of procalcitonin (ProCT) as a diagnostic marker of …
H Dalal, M Dahlgren, S Gladchuk, C Brueffer… - Scientific reports, 2022 - nature.com
Estrogen receptor alpha (ERα, encoded by ESR1) is a well-characterized transcription factor expressed in more than 75% of breast tumors and is the key biomarker to direct endocrine …
B Gold, M Cankovic, LV Furtado, F Meier… - The Journal of Molecular …, 2015 - Elsevier
Diagnosing and screening for tumors through noninvasive means represent an important paradigm shift in precision medicine. In contrast to tissue biopsy, detection of circulating …
H Schwarzenbach - Breast cancer research, 2013 - Springer
During tumor development, tumor cells release their nucleic acids into the blood circulation. This process occurs by apoptotic and necrotic cell deaths along with active cell secretion …
Y Zhou, X Liu - Biomarker research, 2020 - Springer
Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment …
MC Louie, MB Sevigny - American journal of cancer research, 2017 - ncbi.nlm.nih.gov
Despite the existence of many promising anti-cancer therapies, not all breast cancers are equally treatable, due partly to the fact that focus has been primarily on a few select breast …
The aim of the present study was to investigate whether methylation of the angiotensin I converting enzyme 2 (ACE2) promoter increases the risk of essential hypertension (EH). A …
JH Lee, H Jeong, JW Choi, HE Oh, YS Kim - Medicine, 2018 - journals.lww.com
Background: Liquid biopsies using circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) have been developed for early cancer detection and patient monitoring. To …